JP2016530279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530279A5 JP2016530279A5 JP2016537894A JP2016537894A JP2016530279A5 JP 2016530279 A5 JP2016530279 A5 JP 2016530279A5 JP 2016537894 A JP2016537894 A JP 2016537894A JP 2016537894 A JP2016537894 A JP 2016537894A JP 2016530279 A5 JP2016530279 A5 JP 2016530279A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- sustained release
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 238000013268 sustained release Methods 0.000 claims description 23
- 239000012730 sustained-release form Substances 0.000 claims description 23
- 230000036470 plasma concentration Effects 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 20
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 12
- 231100000057 systemic toxicity Toxicity 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 229940109239 creatinine Drugs 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000006289 Rett Syndrome Diseases 0.000 claims description 4
- 208000017849 acquired lipodystrophy Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 208000006132 lipodystrophy Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010053857 partial lipodystrophy Diseases 0.000 claims description 4
- 231100000816 toxic dose Toxicity 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 241000406668 Loxodonta cyclotis Species 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019162622A JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872294P | 2013-08-30 | 2013-08-30 | |
| US61/872,294 | 2013-08-30 | ||
| US201361919003P | 2013-12-20 | 2013-12-20 | |
| US61/919,003 | 2013-12-20 | ||
| PCT/US2014/053406 WO2015031756A1 (en) | 2013-08-30 | 2014-08-29 | Novel 2,4-dinitrophenol formulations and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162622A Division JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530279A JP2016530279A (ja) | 2016-09-29 |
| JP2016530279A5 true JP2016530279A5 (enExample) | 2017-09-07 |
| JP6706204B2 JP6706204B2 (ja) | 2020-06-03 |
Family
ID=52587363
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537894A Active JP6706204B2 (ja) | 2013-08-30 | 2014-08-29 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| JP2019162622A Active JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| JP2021113956A Active JP7359809B2 (ja) | 2013-08-30 | 2021-07-09 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
| JP2023127746A Pending JP2023133603A (ja) | 2013-08-30 | 2023-08-04 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162622A Active JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| JP2021113956A Active JP7359809B2 (ja) | 2013-08-30 | 2021-07-09 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
| JP2023127746A Pending JP2023133603A (ja) | 2013-08-30 | 2023-08-04 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10786466B2 (enExample) |
| EP (1) | EP3038611B1 (enExample) |
| JP (4) | JP6706204B2 (enExample) |
| CN (2) | CN110302385A (enExample) |
| WO (1) | WO2015031756A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302385A (zh) | 2013-08-30 | 2019-10-08 | 耶鲁大学 | 新型2，4-二硝基苯酚制剂和使用其的方法 |
| CN116617195A (zh) | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
| DE102015016801A1 (de) * | 2015-12-23 | 2017-06-29 | Christian Windisch | Chemotherapeutisches Verfahren zur Behandlung maliger Geschwülste durch "Entkopplung" der oxidativen Phosphorilierung ("Krebsatmung") in aerob glycolysierenden Zellen (Krebszellen) |
| JP7021098B2 (ja) * | 2016-03-07 | 2022-02-16 | マイトコン ファーマシューティカルズ， インコーポレイテッド | 神経筋、神経変性、自己免疫、発達、外傷性脳損傷、震とう、ドライアイ疾患および／または代謝性疾患のｄｎｐおよびｄｎｐプロドラッグ処置 |
| GEP20217227B (en) | 2017-01-06 | 2021-02-25 | Pharmaceuticals Inc Rivus | Novel phenyl derivatives |
| WO2019217164A1 (en) * | 2018-05-09 | 2019-11-14 | Reyoung Corporation | Compositions and methods for treating cancer and other diseases |
| US20200397807A1 (en) | 2019-06-18 | 2020-12-24 | MitoPower, LLC | Nicotinyl riboside compounds and their uses |
| CN110237033A (zh) * | 2019-07-30 | 2019-09-17 | 成都医学院 | 一种2,4二硝基苯酚注射液及其制备方法和用途 |
| CN110302154B (zh) * | 2019-07-30 | 2021-09-10 | 成都医学院 | 一种2,4-二硝基苯酚脂肪乳及其制备方法和用途 |
| CN113045428B (zh) * | 2019-12-26 | 2022-04-22 | 中国农业大学 | 化合物及其在减脂中的用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA774573A (en) | 1967-12-26 | Sehring Richard | Derivatives of 2-hydroxy-3,5-dinitrobenzyl alcohol | |
| US2183589A (en) | 1939-12-19 | Derivatives of compounds of the | ||
| US1695656A (en) | 1927-03-10 | 1928-12-18 | Firm Gehe & Co A G | Method of producing narcotica |
| US3081224A (en) | 1959-01-21 | 1963-03-12 | American Cyanamid Co | Methods of removing helminths employing halogenated nitrophenols and their derivatives |
| NL301998A (enExample) | 1962-12-27 | 1900-01-01 | ||
| DE3313905A1 (de) | 1983-04-16 | 1984-10-25 | Henkel KGaA, 4000 Düsseldorf | Neue 2.4-diaminophenolether als kuppler fuer oxidationshaarfaerbemittel |
| DE3515339A1 (de) | 1985-04-27 | 1986-10-30 | Cassella Ag, 6000 Frankfurt | Verfahren zur herstellung von 2,4-dinitrophenylethern |
| CN1011660B (zh) * | 1986-04-23 | 1991-02-20 | 吴佩璇 | 一种含三硝基苯、田螺的药品合成方法 |
| US5078908A (en) | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
| US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
| IN192400B (enExample) * | 1995-06-14 | 2004-04-10 | Council Scient Ind Res | |
| CA2180903A1 (en) | 1995-07-11 | 1997-01-12 | Kunio Sugisawa | Pesticidal composition to noxious organisms |
| EP1073693A1 (en) | 1998-04-24 | 2001-02-07 | Eastman Chemical Company | Coprecipitation of cellulose esters with functional additives and compositions thus obtainable |
| US7635722B1 (en) * | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
| US6664297B1 (en) | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| EP1429734B1 (en) * | 2001-09-21 | 2007-12-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
| EP1545477A4 (en) | 2002-09-13 | 2006-11-22 | Cydex Inc | CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN |
| EP1575575B1 (en) | 2002-11-08 | 2010-05-19 | High Point Pharmaceuticals, LLC | Safe chemical uncouplers for the treatment of obesity |
| WO2007050673A2 (en) | 2005-10-25 | 2007-05-03 | University Of Florida | Cyclin dependent kinase inhibitors |
| EP2196453A1 (en) | 2008-12-10 | 2010-06-16 | Cellvir | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents |
| WO2011053825A2 (en) * | 2009-10-30 | 2011-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment or prevention of mitochondrial diseases |
| JP2013209295A (ja) * | 2010-10-13 | 2013-10-10 | Takeda Chem Ind Ltd | ペプチド誘導体 |
| CN110302385A (zh) * | 2013-08-30 | 2019-10-08 | 耶鲁大学 | 新型2，4-二硝基苯酚制剂和使用其的方法 |
-
2014
- 2014-08-29 CN CN201910726120.2A patent/CN110302385A/zh active Pending
- 2014-08-29 WO PCT/US2014/053406 patent/WO2015031756A1/en not_active Ceased
- 2014-08-29 JP JP2016537894A patent/JP6706204B2/ja active Active
- 2014-08-29 EP EP14839060.2A patent/EP3038611B1/en active Active
- 2014-08-29 CN CN201480059363.0A patent/CN105682653B/zh active Active
- 2014-08-29 US US14/911,322 patent/US10786466B2/en active Active
-
2019
- 2019-09-06 JP JP2019162622A patent/JP6913137B2/ja active Active
-
2020
- 2020-07-22 US US16/936,316 patent/US11433033B2/en active Active
-
2021
- 2021-07-09 JP JP2021113956A patent/JP7359809B2/ja active Active
-
2022
- 2022-05-16 US US17/663,586 patent/US11883369B2/en active Active
-
2023
- 2023-08-04 JP JP2023127746A patent/JP2023133603A/ja active Pending
-
2024
- 2024-08-22 US US18/812,381 patent/US20250228793A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530279A5 (enExample) | ||
| Wedemeyer et al. | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection | |
| WO2008085484A3 (en) | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid | |
| JP6913137B2 (ja) | 新規２，４−ジニトロフェノール製剤およびその使用法 | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| JP2015519329A5 (enExample) | ||
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| EP3684344B1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| JP7651620B2 (ja) | 経口リファマイシンｓｖ組成物 | |
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP6986445B2 (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2020526553A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| JP2019501226A5 (enExample) | ||
| RU2019110779A (ru) | Новые схемы введения агонистов fxr | |
| JP2016505050A5 (enExample) | ||
| RU2013105504A (ru) | Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| JP2019507785A5 (enExample) | ||
| JP2011500650A5 (enExample) | ||
| JP2019535830A5 (enExample) | ||
| RU2020121222A (ru) | Агонисты fxr для лечения заболеваний печени | |
| EA201990883A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения |